News | April 24, 2026
Rossari Biotech reviews capex, delays Unitop and Tristar expansion rollout
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
Phase I to supply clean energy to five facilities, with long-term plans to power 19 hospitals through a 30 MW renewable network
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Subscribe To Our Newsletter & Stay Updated
